Cigna Group (CI)
Fair bewertetFundamental
78
Kurs
$271.83
Marktkapitalisierung
$71.83B
Teil 1 · Was das Unternehmen wert ist
Übersicht
The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. It operates through two segments: Evernorth Health Services and Cigna Healthcare. The Evernorth Health Services segment includes Pharmacy Benefit Services and Specialty and Care Services, offering pharmacy benefit management, drug claim adjudication, retail pharmacy network administration, benefit design consultation, drug utilization review, drug formulary management, pharmacy benefits, home delivery pharmacy, specialty pharmacy, specialty pharmaceutical distribution, and clinical programs for whole-person health outcomes. The Cigna Healthcare segment comprises U.S. Healthcare and International Health, delivering comprehensive medical and coordinated solutions such as employer medical plans, individual and family plans, behavioral health, consumer health engagement, dental, pharmacy management, stop-loss insurance, global health care, and local health care solutions, as well as health care benefits for mobile individuals and employees of multinational organizations. The company offers other operations, including corporate-owned life insurance, reinsurance, and certain run-off and non-strategic businesses. The company distributes its products and services through brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was formerly known as Cigna Corporation and changed its name to The Cigna Group in February 2023. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 18. September 2026 with claude-haiku-4-5 — shared with all users
It is the closest mirror image of Cigna, selling employer-sponsored health plans to the same large US corporate clients while its Optum Rx pharmacy benefit manager bids against Evernorth's Express Scripts for the same drug-benefit contracts.
Through Aetna it competes for the same commercial and employer health members, and through CVS Caremark it is one of the three pharmacy benefit managers that split the US market with Express Scripts.
As the largest Blue Cross Blue Shield operator it bids for the same employer and individual health plans in overlapping US states, and its CarelonRx unit competes directly with Evernorth on pharmacy benefits.
It is the biggest insurer on the US individual insurance marketplaces, where it competes with Cigna Healthcare for the same subsidised individual customers state by state.
This mutual Blue Cross insurer covering Illinois, Texas and three other states is the fifth-largest US commercial carrier and now also owns the Medicare business Cigna sold it in March 2025, putting the two head to head on national employer accounts.
Bilanz & Liquidität
Umsatz
$282.38B
Letzte 12 Monate (bis 30.6.2026)
Nettogewinn
$6.42B
Letzte 12 Monate (bis 30.6.2026)
Freier Cashflow
-
Gesamtes Eigenkapital
$41.71B
Gesamtverbindlichkeiten
$116.05B
Current Ratio
0.85
Zinsdeckungsgrad
7.03
Schulden/EBITDA
2.75
Gewinn je Aktie
Umsatz & Nettogewinn
Freier Cashflow
Ertragsaufschlüsselung
Historische Aufstellung
Margen im Zeitverlauf
Verschuldung im Zeitverlauf
Wie schwer die Schulden wiegen
Wachstumsraster
Wachstum — Umsatz
Innerer-Wert-Schätzung
Innerer Wert
$324.54
Aktueller Kurs
$271.83
Sicherheitsmarge
+16.2%
Innerer-Wert-Spanne
$210.95 - $438.13
Streubreite zwischen den verwendeten Bewertungsmethoden, kein statistisch kalibriertes Konfidenzintervall.
Bewertungsmethoden
Bewertungskennzahlen
P/E-Verhältnis
11.25
ROE
14.3%
P/B-Verhältnis
1.69
P/FCF
-
Bruttomarge
20.6%
ROIC
7.8%
Rentabilitäts-Radar
Wertschöpfung (Wettbewerbsvorteil)
ROIC
7.8%
WACC
6.5%
ROIC − WACC
+1.2 pp
Der ROIC übersteigt die Kapitalkosten: Das Unternehmen schafft Wert für die Aktionäre.
Fundamentalanalyse-Kriterien
Bestanden (18)
- EPS shows upward trend
- EPS CAGR 13.33%
- Price CAGR 7.73%
- ROIC 7.7%
- P/B Ratio 1.69
- Debt/Equity ratio
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Price below Graham Number
- ROE 15.2%
- Revenue Growth 5Y 11.4%
- Analyst Consensus 76% Buy
- Earnings Quality (OCF/NI) 1.60
- Share Dilution -5.2%
- Net Margin Trend 2.3% vs 1.9%
- Piotroski F-Score 8/9
Nicht bestanden (5)
- Gross Margin 20.6%
- Operating Margin 3.5%
- Low reliance on intangibles
- DCF valuation (Fairly valued)
- Earnings Surprise avg -0.6%
Nicht verfügbar (5)
- P/FCF NaN
- Dividend Payout NaN%
- Positive Free Cash Flow
- CapEx intensity
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Starke finanzielle Gesundheit
Gewinnqualität
Hohe Qualität: Gewinne durch Cashflow gedeckt
Aktienverwässerung
Aktienrückkäufe. Aktionärsfreundlich
Institutionelle Beteiligungen
Unternehmensführung
Führungsteam
| Name | Position | Alter |
|---|---|---|
| Mr. David Michael Cordani | Executive Chairman of the Board | 60 |
| Mr. Brian Case Evanko C.F.A. | President, CEO & Director | 48 |
| Ms. Ann M. Dennison | Executive VP & CFO | 54 |
| Ms. Nicole Susan Jones J.D. | Executive Vice President, Chief Administrative Officer & Chief Human Resources Officer | 54 |
| Mr. F. Everett Neville | Executive VP & Special Advisor to the CEO | 60 |
| Ms. Jamie Kates | Senior VP & Tax and Global Chief Accounting Officer | 44 |
| Mr. Durga Prasad Koka | Executive Vice President & Global Chief Information Officer | - |
| Mr. Ralph Giacobbe | Senior Vice President of Investor Relations | - |
| Ms. Andrea Nelson | EVP, General Counsel & Corporate Secretary | - |
| Ms. Melissa Skottegaard | Executive Vice President, Chief Marketing & Communications Officer | - |
Prüfungsrisiko
1
Vorstandsrisiko
4
Vergütungsrisiko
7
Aktionärsrechterisiko
7
Teil 2 · Der Preis und der Einstiegszeitpunkt
Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.
Dokumente
- Dokument ansehen
Jahresbericht (10-K)
Ein jährlicher Überblick über das Geschäft, die Finanzergebnisse und die Risiken des Unternehmens.
Eingereicht am 2026-02-26
- Dokument ansehen
Quartalsbericht (10-Q)
Ein Update zur finanziellen Entwicklung der letzten drei Monate.
Eingereicht am 2026-07-30
- Dokument ansehen
Ad-hoc-Meldung (8-K)
Eine Mitteilung über ein wichtiges Ereignis, etwa einen Führungswechsel oder eine bedeutende Ankündigung.
Eingereicht am 2026-09-30
via SEC EDGAR
Ertragshistorie
via SEC EDGAR
Latest News
Recent headlines for CI, sourced from Markets Gazette.
- 23d agoNEUTRALCigna Healthcare on Business Strategy
Jason Sadler, International Health Global President at Cigna Healthcare, provided insights into the company's business strategy, addressing the dual forces of increasing AI adoption and escalating healthcare expenditures. While the discussion highlights Cigna's navigation of these significant industry trends, it does not present specific financial figures or forward-looking guidance that would indicate a definitive positive or negative impact on the company's immediate stock performance. Investors will monitor Cigna's strategic execution in response to these evolving market dynamics.
- 5/22/2026NEUTRALHere's How Much You Would Have Made Owning Cigna Group Stock In The Last 20 Years
An analysis of The Cigna Group's stock performance over the past two decades reveals a significant historical return for investors. While specific figures are not detailed in this summary, the article implies substantial long-term gains. This historical perspective is crucial for investors evaluating Cigna's potential for future growth and stability, offering insights into its resilience and market position through various economic cycles. The focus remains on past performance rather than current catalysts.
- 3/6/2026POSITIVEHere's How Much $1000 Invested In Cigna Group 15 Years Ago Would Be Worth Today
An investment of $1000 in Cigna Group 15 years ago would have grown to approximately $10,500 today, representing a substantial return on investment. This performance highlights the company's long-term growth trajectory and its ability to generate significant shareholder value over an extended period. Investors who held Cigna stock through various market cycles would have benefited from its strategic initiatives and market positioning within the health insurance and services sector. The impressive growth suggests a robust business model and effective management.
- 3/3/2026NEGATIVECigna Stock Falls After CEO Retirement Announcement
Shares of The Cigna Group (NYSE:CI) experienced a significant decline on Tuesday, following the announcement of CEO David Cordani's retirement. The news immediately triggered a negative market reaction, highlighting investor sensitivity to leadership changes in major corporations. Cordani, a key figure for the healthcare giant, leaves a void that generates uncertainty about the company's future strategic and operational direction. Analysts suggest that the leadership transition could lead to a period of volatility for the stock, as the market awaits clarity on subsequent plans and the identity of the successor. For investors, this event underscores the importance of managerial stability in complex sectors like healthcare.
- 3/3/2026NEUTRALCigna’s longtime CEO to step down as health insurers face growing scrutiny
Cigna Group, a major player in the health insurance sector, has announced a significant leadership transition. David Cordani, who has served as CEO for an impressive 27 years, will step down. He will be succeeded by Brian Evanko, a seasoned company veteran, ensuring a degree of continuity in leadership. This change comes at a time when health insurers are facing increased scrutiny, adding complexity to the new CEO's mandate. For investors, the appointment of an internal successor like Evanko suggests a focus on stability and a continuation of existing strategies, potentially mitigating immediate market volatility. However, the broader industry challenges mean Evanko will need to navigate a demanding regulatory and competitive landscape, making his strategic direction crucial for Cigna's future performance.
via Markets Gazette